Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NUC-1031 |
Synonyms | |
Therapy Description |
NUC-1031 is a gemicitabine-derivative pyrimidine analogue prodrug that is converted into the products dFdCDP and dFdCTP, which reduce the nucleotide pool for DNA replication and inhibit DNA synthesis, respectively, potentially resulting in increased tumor cell apoptosis (PMID: 30206366, PMID: 31113993). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NUC-1031 | gemcitabine ProTide|Fosgemcitabine Palabenamide|NUC 1031|Acelarin | Chemotherapy - Antimetabolite 14 | NUC-1031 is a gemicitabine-derivative pyrimidine analogue prodrug that is converted into the products dFdCDP and dFdCTP, which reduce the nucleotide pool for DNA replication and inhibit DNA synthesis, respectively, potentially resulting in increased tumor cell apoptosis (PMID: 30206366, PMID: 31113993). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|